Jun 14, 2026Metabolic Therapeutics

Tirzepatide vs. Semaglutide: More Fat Loss, Not Proven Appetite Edge

A 28-week head-to-head trial found greater weight and fat loss with tirzepatide than semaglutide 1 mg—but appetite superiority remains unproven.

tirzepatidesemaglutideweight losstype 2 diabetes

Read article →

Mar 29, 2026Cardiometabolic Drugs

Tirzepatide Safety in Heart-Risk Diabetes: What We Know

Tirzepatide can improve weight and glucose control, but what do cardiovascular-risk trials show about nausea, serious harm, and mortality?

tirzepatideglp-1 agonisttype 2 diabetescardiovascular risk

Read article →

Mar 28, 2026Cardiovascular Health

Tirzepatide and SGLT2 Inhibitors Show an AF Signal

Can tirzepatide and SGLT2 inhibitors reduce atrial fibrillation burden? New data link metabolic therapy to fewer AF procedures, but trials must confirm it.

tirzepatideatrial fibrillationglp-1 agoniststype 2 diabetes

Read article →

Mar 27, 2026Metabolic Health

Tirzepatide and MASH: Can Weight Loss Track Liver Healing?

Tirzepatide resolved MASH on biopsy in phase 2 data. Can 10% weight loss, triglycerides, and MRI markers help track liver response?

tirzepatidemashliver fibrosisweight loss

Read article →

Mar 27, 2026Cardiovascular Health

GLP-1 Drugs and Heart Failure: What an NNT of 80 Means

GLP-1 drugs reduce heart failure events modestly overall, with stronger signals in obesity. See what the NNTs, limits, and next-generation drugs mean.

glp-1 agonistssemaglutidetirzepatideheart failure

Read article →

Mar 26, 2026Body Composition

GLP-1 Weight Loss: How Much Is Lean Mass?

A 2026 meta-analysis compares lean-mass loss on semaglutide, tirzepatide, and dieting—and shows why resistance training matters most.

semaglutidetirzepatideglp-1 agonistslean mass loss

Read article →

Mar 21, 2026Glp 1 Agonists

47 GLP-1 Trials: What the Pooled Weight-Loss Result Means

A 47-trial GLP-1 meta-analysis found lower weight, BMI, and waist size—but pooled results hide major differences by drug and diabetes status.

tirzepatidesemaglutideglp-1 agonistliraglutide

Read article →

Mar 21, 2026Obesity Drugs

Obesity Drug Guidelines: What GRADE Says Actually Works

New GRADE obesity guidelines rank tirzepatide and semaglutide highest, but indirect comparisons, lean-mass loss, cost, and access still matter.

glp-1semaglutidetirzepatideweight loss drugs

Read article →

Mar 17, 2026Nutrition

Semaglutide vs. Bariatric Surgery for Heart Health

Does semaglutide protect the heart as well as bariatric surgery? Compare MACE, heart failure, blood pressure, and the limits of current evidence.

semaglutidetirzepatideglp-1 agonistsbariatric surgery

Read article →

Mar 14, 2026Obesity Pharmacology

GLP-1 Receptor Agonists for Obesity: Benefits and Risks

GLP-1 drugs deliver unusually large weight loss and may improve cardiovascular outcomes, but GI effects, lean mass, surgery, and long-term use complicate choice.

semaglutidetirzepatideglp-1 agonistsweight loss

Read article →

Mar 13, 2026Sleep

Tirzepatide Cuts Sleep Apnea Severity in Obesity—With Limits

Tirzepatide reduced AHI by about 22 events per hour in obesity-related sleep apnea, but it does not yet replace CPAP for cardiovascular risk.

sleep apneatirzepatidemetabolic healthahi reduction

Read article →

Mar 13, 2026Sleep

Tirzepatide for Sleep Apnea: Big Results, Unproven Mechanism

Tirzepatide cuts sleep-apnea severity in trials, largely through weight loss. Does it help beyond weight loss? The evidence has not proved it.

tirzepatidesleep apneaglp-1weight loss

Read article →

Page 1 of 2Next →